Amgen, Kyowa Kirin to co-develop and market atopic dermatitis drug KHK4083
KHK4083 is an anti-OX40 fully human monoclonal antibody, developed by Kyowa Kirin to treat atopic dermatitis and other…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
02 Jun 21
KHK4083 is an anti-OX40 fully human monoclonal antibody, developed by Kyowa Kirin to treat atopic dermatitis and other…
02 Jun 21
BridgeBio, through its affiliate QED and partner Helsinn, intends to co-commercialise the cholangiocarcinoma drug in the US
01 Jun 21
The new move will allow Samsung Biologics to provide end-to-end mRNA vaccine manufacturing services from bulk drug substance…
01 Jun 21
The agreement will enable Innovent to co-develop and commercialise AnHeart’ taletrectinib in Greater China, including mainland China, Hong…
31 May 21
MHRA approved Covid-19 Vaccine Janssen after meeting the required safety, quality and effectiveness standards
31 May 21
The EC approval is based on results from the Phase 3 ADAURA trial, in which Tagrisso reduced the…
28 May 21
Zeposia is claimed to be the first and only S1P receptor modulator approved for treating moderately to severely…
28 May 21
Through a two-stage design, the phase 3 trial will evaluate vaccine formulations targeting original D.614 virus along with…
27 May 21
In Phase 3 COMET-ICE trial, sotrovimab reduced 85% risk of hospitalisation or death in high-risk adult patients compared…
26 May 21
Venclyxto-based combination treatments are indicated for adults with newly diagnosed AML, who are not eligible for intensive chemotherapy